Treatment Information

Back

Lung Cancer treatment details. Biologic therapy.

Sarah Cannon Research Institute, Nashville, TN, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Nashville, TN
Treatments:Biologic therapyHospital:Sarah Cannon Research Institute
Drugs:Journal:Link
Date:Jun 2011

Description:

Patients:
This study involved previously treated advanced non-small cell lung cancer patients who were divided into 2 treatment groups. Group A consisted of 111 patients with a median age of 65 years and 56% were male. Group B had 55 patients with a median age of 65 years and 47% male.

Treatment:
Group A was treated with the biologic therapy agents sorafenib and erlotinib. Group B was given erlotinib and a placebo.

Toxicities:
The maximum toxicity reported for group A was of grade 4, including grade 3/4 diarrhea (15% of patients), fatigue (14%), and anorexia (10%).

There was one treatment-related death due to diarrhea in group B. Grade 3/4 rash (13%) and anorexia (9%) were also reported.

Results:
The median overall survival for groups A and B was 7.62 and 7.23 months, respectively.

Support:
This study was supported by the pharmaceutical companies Bayer HealthCare, Onyx, and OSI.

Correspondence: David R. Spigel; email: [email protected]



Back